Selegiline and Solriamfetol (Sunosi): interaction and safety
This source-based reference is not a personal treatment recommendation. The relevance and management of an interaction depend on the exact products, route, dose and clinical situation.
Interaction mechanism
Solriamfetol and MAO inhibitors present a risk of hypertensive reactions.
Clinical significance and safety
Selegiline and Solriamfetol (Sunosi): Solriamfetol and MAO inhibitors present a risk of hypertensive reactions. The cited label prohibits use during MAOI treatment and within 14 days after stopping an MAOI; restrictions for the reverse switch must also be checked. MAOI contraindications and product-specific waiting intervals must be checked before co-treatment or switching; a patient should not plan a washout or abruptly stop regular treatment without the treating team.
Using this information
This is a source-based reference record, not a recommendation to combine, stop or change medicines. A missing interaction record does not establish safe use. A qualified healthcare professional should consider the exact products, doses, other medicines and individual health circumstances.